| Members |
targetComponentId |
| Chloral hydrate 143mg/5mL elixir |
Chloral hydrate 28.6 mg/mL oral solution |
| Chloral hydrate 500mg/5mL syrup |
Product containing precisely chloral hydrate 100 milligram/1 milliliter conventional release oral solution (clinical drug) |
| Chloral sedative adverse reaction |
Adverse reaction to chloral and/or chloral derivative (disorder) |
| Chloral sedative allergy |
Allergy to chloral derivative |
| Chloral sedative overdose |
Chloral and/or chloral derivative overdose |
| Chloramine |
Monochloramine |
| Chloramine measurement |
Monochloramine measurement |
| Chloramphenicol 0.5% preservative-free eye drops |
Chloramphenicol 5 mg/mL eye drops |
| Chlorhexidine 0.5% powder |
Product containing chlorhexidine (medicinal product) |
| Chlorhexidine acetate 1% dusting powder |
Chlorhexidine diacetate 10 mg/g cutaneous powder |
| Chlorhexidine acetate 1% dusting powder |
Chlorhexidine diacetate 10 mg/g cutaneous powder |
| Chlorhexidine gluconate 0.2% mouthwash |
Product containing precisely chlorhexidine gluconate 2 milligram/1 milliliter conventional release oromucosal solution (clinical drug) |
| Chlorhexidine gluconate 5% concentrated solution |
Chlorhexidine gluconate 50 mg/mL cutaneous solution |
| Chlorhexidine gluconate+chlorbutol 0.1/0.5% mouthwash |
Chlorhexidine gluconate 1 mg/mL and chlorobutanol 5 mg/mL oromucosal solution |
| Chlorhexidine hydrochloride and neomycin sulfate adverse reaction |
Adverse reaction to chlorhexidine and/or neomycin |
| Chlorhexidine obstetric 1% cream |
Chlorhexidine gluconate 10 mg/g cutaneous cream |
| Chloride modified diet |
Chloride salt modified diet (regime/therapy) |
| Chlormethiazole edisylate 250mg/5mL syrup |
Clomethiazole (as clomethiazole edisilate) 50 mg/mL oral solution |
| Chlormethiazole edisylate 8mg/mL infusion |
Product containing clomethiazole (medicinal product) |
| Chlormethiazole edisylate 8mg/mL infusion |
Product containing clomethiazole (medicinal product) |
| Chlorofluorocarbon |
Chlorofluorocarbon |
| Chlorofluorocarbon |
Freon |
| Chloroform |
Chloroform |
| Chloroquine phosphate 80mg/5mL syrup |
Product containing precisely chloroquine phosphate 16 milligram/1 milliliter conventional release oral solution (clinical drug) |
| Chloroquine sulfate 68mg/5mL syrup |
Product containing precisely chloroquine sulfate 13.6 milligram/1 milliliter conventional release oral solution (clinical drug) |
| Chlorpheniramine maleate 10mg/1mL injection |
Chlorphenamine maleate 10 mg/mL solution for injection |
| Chlorpheniramine maleate 2mg/5mL sugar free syrup |
Chlorphenamine maleate 400 microgram/mL oral solution |
| Chlorpheniramine maleate 2mg/5mL syrup |
Chlorphenamine maleate 400 microgram/mL oral solution |
| Chlorpromazine hydrochloride 100mg/5mL s/f oral solution |
Chlorpromazine hydrochloride 20 mg/mL oral solution |
| Chlorpromazine hydrochloride 100mg/5mL s/f suspension |
Chlorpromazine hydrochloride (as chlorpromazine embonate) 20 mg/mL oral suspension |
| Chlorpromazine hydrochloride 100mg/5mL syrup |
Chlorpromazine hydrochloride 20 mg/mL oral solution |
| Chlorpromazine hydrochloride 25mg injection solution 1mL vial |
Product containing precisely chlorpromazine hydrochloride 25 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Chlorpromazine hydrochloride 25mg/1mL injection |
Product containing precisely chlorpromazine hydrochloride 25 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Chlorpromazine hydrochloride 25mg/1mL injection |
Product containing precisely chlorpromazine hydrochloride 25 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Chlorpromazine hydrochloride 25mg/5mL s/f oral solution |
Chlorpromazine hydrochloride 5 mg/mL oral solution |
| Chlorpromazine hydrochloride 25mg/5mL syrup |
Chlorpromazine hydrochloride 5 mg/mL oral solution |
| Chlorpromazine hydrochloride 25mg/mL injection |
Product containing precisely chlorpromazine hydrochloride 25 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Chlorpromazine hydrochloride 25mg/mL injection solution 2mL ampule |
Product containing precisely chlorpromazine hydrochloride 25 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Chlorpromazine hydrochloride 50mg/2mL injection |
Product containing precisely chlorpromazine hydrochloride 25 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Choanotaenia species |
Choanotaenia |
| Choking |
Choking sensation (finding) |
| Choking |
Choking |
| Choking: [symptom] or [sensation] |
Choking sensation (finding) |
| Cholangiopancreatography catheter, reusable |
Cholangiopancreatography catheter (physical object) |
| Cholangiopancreatography catheter, single-use |
Cholangiopancreatography catheter (physical object) |
| Cholecalciferol or ergocalciferol |
Product containing colecalciferol (medicinal product) |
| Cholecalciferol or ergocalciferol |
Product containing ergocalciferol (medicinal product) |
| Cholecystectomy: [total NEC] or [NEC] |
Cholecystectomy |
| Cholecystoenterostomy |
Cholecystojejunostomy |
| Cholecystojejunostomy (& Roux en Y) |
Cholecystojejunostomy |
| Cholecystojejunostomy (& Roux en Y) |
Roux-en-Y cholecystojejunostomy |
| Cholecystokinin measurement |
Measurement of cholecystokinin in serum |
| Choledocholithotomy |
Choledocholithotomy (procedure) |
| Choledocholithotomy |
Bile duct stone removal (procedure) |
| Choledocholithotomy |
Choledochostomy with removal of calculus |
| Choledocholithotomy: [open NEC] or [NEC] |
Bile duct stone removal (procedure) |
| Cholelithiasis |
Calculus of bile duct |
| Cholelithiasis |
Gallstone |
| Cholelithiasis |
Biliary calculus |
| Cholelithiasis |
Calculus of cystic duct |
| Cholera contact |
Exposure to Vibrio cholerae (event) |
| Cholera contact |
Exposure to Vibrio cholerae (event) |
| Cholera vaccine |
Vibrio cholerae antigen-containing vaccine product |
| Cholera vaccine |
Vibrio cholerae antigen-containing vaccine product |
| Cholesteatoma &/or aural polyp |
Cholesteatoma of middle ear |
| Cholesteatoma &/or aural polyp |
Cholesteatoma and aural polyp |
| Cholesteatoma of middle ear AND/OR mastoid |
Cholesteatoma of middle ear and mastoid (disorder) |
| Cholesteatoma of middle ear and mastoid structure |
Cholesteatoma of middle ear and mastoid (disorder) |
| Cholesterol embolization syndrome |
Cholesterol embolus syndrome |
| Cholesterol embolization syndrome |
Ischemic toe |
| Cholesterol-related arthritis and periarthritis |
Secondary osteoarthritis (disorder) |
| Cholestyramine 4g/sachet powder sugar free |
Colestyramine 4 g powder for oral suspension sachet |
| Cholestyramine sug free powder 4g/sachet |
Colestyramine 4 g powder for oral suspension sachet |
| Cholestyramine sug free powder 4g/sachet |
Colestyramine 4 g powder for oral suspension sachet |
| Cholestyramine sugar free powder |
Colestyramine 4 g powder for oral suspension sachet |
| Cholinergic anaphylactoid reaction |
Non-allergic anaphylaxis caused by parasympathomimetic agent |
| Cholinergic anaphylactoid reaction |
Non-allergic anaphylaxis caused by organic phosphorous compound (disorder) |
| Cholinesterase genotype |
Butyrylcholinesterase genotype determination (procedure) |
| Cholinesterase genotype |
Butyrylcholinesterase genotype determination (procedure) |
| Cholinesterase genotype |
Butyrylcholinesterase genotype determination (procedure) |
| Cholinesterase genotype determination |
Butyrylcholinesterase genotype determination (procedure) |
| Cholinesterase inhibitor |
Acetylcholinesterase inhibitor (disposition) |
| Cholinesterase measurement |
Butyrylcholinesterase measurement (procedure) |
| Cholinesterase phenotype |
Butyrylcholinesterase phenotype determination (procedure) |
| Cholinesterase phenotype |
Butyrylcholinesterase phenotype determination (procedure) |
| Cholinesterase phenotype determination |
Butyrylcholinesterase phenotype determination (procedure) |
| Cholinesterase reactivator |
Acetylcholinesterase reactivator |
| Cholinesterase reactivator adverse reaction |
Acetylcholinesterase reactivator adverse reaction (disorder) |
| Cholinesterase screening test |
Butyrylcholinesterase screening test |
| Chondrocalcinosis due to dicalcium phosphate crystals, of the forearm |
Chondrocalcinosis caused by dicalcium phosphate crystals |
| Chondrocalcinosis due to dicalcium phosphate crystals, of the lower leg |
Chondrocalcinosis caused by dicalcium phosphate crystals |
| Chondrocalcinosis due to dicalcium phosphate crystals, of the upper arm |
Chondrocalcinosis of shoulder region caused by dicalcium phosphate crystals (disorder) |
| Chondrocalcinosis due to pyrophosphate crystals of: [lower leg] or [knee] |
Chondrocalcinosis of knee joint caused by pyrophosphate crystals |
| Chondrocalcinosis due to pyrophosphate crystals, of the forearm |
Chondrocalcinosis caused by pyrophosphate crystals (disorder) |
| Chondrocalcinosis due to pyrophosphate crystals, of the lower leg |
Chondrocalcinosis of knee joint caused by pyrophosphate crystals |
| Chondrocalcinosis due to pyrophosphate crystals, of the upper arm |
Chondrocalcinosis of shoulder region caused by pyrophosphate crystals |
| Chondrodysplasia punctata, Conradi-Hünermann type |
Chondrodysplasia punctata, Conradi-Hünermann type (disorder) |
| Chondrodysplasia punctata, Conradi-Hünermann type |
Chondrodysplasia punctata, X-linked dominant type (disorder) |
| Chondrodysplasia, otherwise specified |
Chondrodysplasia (disorder) |
| Chondrodystrophy malacia |
Disorganized development of cartilaginous and fibrous components of the skeleton |
| Chondrodystrophy malacia |
Degenerative disorder |
FHIR